In addition, NUMB has become a predictive biomarker for patients for whom therapy would be appropriate, for example, in patients with prostate cancer who could benefit from NOTCH inhibition or therapies that restore p53 function, such as the Nutlin-related class of anti-MDM2 inhibitors, which are already used in breast cancer [41,189]. The gene discussed is NUMB; the disease is prostate carcinoma.